Patients taking Ozempic for diabetes or weight loss now face a newly recognized threat to their eyesight. Federal regulators in the United States and Europe have each independently flagged non-arteritic anterior ischemic optic neuropathy, known as NAION, as a safety concern linked to semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus. NAION causes sudden, painless vision loss in one eye and has no proven treatment. The accumulating reports from two continents have pushed regulators past routine monitoring and into active evaluation of whether drug labels and prescribing guidance need to change.
Why regulators on two continents flagged semaglutide and NAION at the same time
The FDA listed NAION as a potential serious risk signal for Ozempic during its October through December 2024 review cycle and stated it was evaluating the need for regulatory action. That signal emerged from the FDA Adverse Event Reporting System, or FAERS, the agency’s primary database for collecting and analyzing post-market adverse event reports on drugs and biologics. Separately, Europe’s Pharmacovigilance Risk Assessment Committee, known as PRAC, completed its own assessment and concluded that NAION is a “very rare” side effect of semaglutide medicines. PRAC recommended product information updates for Ozempic, Rybelsus, and Wegovy to reflect that finding.
The convergence matters because the two agencies rely on different reporting pipelines and patient populations. When both reach similar conclusions independently, the statistical noise that plagues any single adverse-event database becomes harder to dismiss. For the millions of people worldwide who take semaglutide, the parallel findings shift the question from whether a signal exists to how large the real-world risk actually is and which patients are most vulnerable.
A key complication is timing. A 2024 study published in JAMA Ophthalmology drew wide attention after researchers reported that clinicians had noticed a cluster of NAION cases among patients using popular weight-loss drugs. That publicity almost certainly drove more doctors and patients to file adverse-event reports, a well-documented phenomenon called stimulated reporting. The hypothesis that NAION reporting rates in FAERS would show a sharp upward bend after that publication is plausible, and it complicates any attempt to read raw report counts as proof of rising incidence. Regulators are aware of this effect, yet the FDA still elevated the signal to a formal review, suggesting the pattern held up even after accounting for reporting bias and background disease risk.
FAERS data and disproportionality analysis point to an accumulating signal
Beyond the FDA’s own signal notice, independent researchers have begun mining the same database for confirmation. A disproportionality analysis published in 2025 examined FAERS records for semaglutide and NAION and found reporting patterns consistent with an emerging pharmacovigilance signal. Disproportionality analysis compares how often a specific drug–event pair appears in the database relative to all other drugs and events. When a particular combination shows up more frequently than expected, it flags a statistical imbalance that warrants closer investigation, even if the absolute number of cases remains small.
This method has clear limits. The FAERS database relies on voluntary submissions from healthcare professionals, patients, and manufacturers. Reports can be incomplete, duplicated, or filed without clinical confirmation. No individual case narrative or de-identified patient record from FAERS or Europe’s EudraVigilance system has been made publicly available with enough detail to assess confounding factors such as diabetes duration, sleep apnea, or prior optic-nerve disease, all of which independently raise NAION risk. The disproportionality finding adds a distinct evidence stream to the clinical observations from the JAMA Ophthalmology study, but it cannot, on its own, establish that semaglutide causes the condition.
NAION itself is uncommon in the general population, typically striking people over 50 who have small optic-disc anatomy and vascular risk factors. Diabetes is a known contributor, which creates a difficult confounding problem: patients prescribed Ozempic for type 2 diabetes already carry elevated baseline risk for the condition. Many people using Wegovy for obesity also have hypertension, high cholesterol, or sleep apnea, each of which may independently damage the optic nerve. Separating the drug’s contribution from the disease’s contribution requires controlled studies that have not yet been completed and may be challenging to design, given the rarity and unpredictability of NAION.
Unanswered questions for patients and prescribers
Several gaps in the evidence remain wide open. No public data release has provided the exact count or temporal trend of NAION reports tied to semaglutide in FAERS, making it impossible for outside researchers to independently verify whether the signal is growing, stable, or inflated by stimulated reporting. The European assessment classifying NAION as “very rare” offers some reassurance that the absolute risk is low, but that language still encompasses a wide numerical range. For an individual patient, “very rare” may feel abstract when the outcome is irreversible vision loss.
Key clinical questions remain unresolved. It is not yet clear whether risk, if real, is concentrated in the first months after starting semaglutide or persists over long-term use. Dose–response relationships are also uncertain: Wegovy is typically prescribed at higher doses than Ozempic, and oral Rybelsus exposes patients to different pharmacokinetics altogether. Without detailed case-level data, clinicians cannot reliably determine whether higher doses, rapid dose escalation, or certain comorbidities amplify the danger.
For now, regulators have stopped short of recommending routine eye screening or discontinuation of semaglutide in patients without symptoms. Instead, they emphasize vigilance: patients should be advised to seek urgent ophthalmic evaluation if they experience sudden vision changes, even if painless and in only one eye. Prescribers may need to incorporate a brief discussion of NAION into informed-consent conversations, particularly for patients who already have optic-nerve crowding, a history of NAION in the other eye, or multiple vascular risk factors that stack the odds against the optic nerve’s blood supply.
Balancing risks and benefits is especially complex in this case because semaglutide can substantially improve glycemic control and promote weight loss, both of which lower the long-term risk of diabetic retinopathy, stroke, and cardiovascular events. For many patients, those established benefits will outweigh a very rare but serious eye complication. Yet the calculus may differ for younger individuals using semaglutide primarily for cosmetic weight loss or for patients with pre-existing optic-nerve vulnerability, where even a small additional risk could tip the balance toward alternative therapies.
Looking ahead, more definitive answers will likely require a combination of approaches: large observational cohort studies comparing NAION incidence in semaglutide users with matched controls; detailed case series that characterize anatomy, comorbidities, and timing; and mechanistic research into how GLP-1 receptor agonists might influence optic-nerve perfusion. Until such data arrive, the emerging signal sits in an uncomfortable middle ground-too consistent to ignore, but too incomplete to justify sweeping changes to clinical practice.
For patients already on Ozempic, Wegovy, or Rybelsus, experts advise against abrupt discontinuation without medical guidance. Instead, they recommend a focused conversation with the prescribing clinician about individual risk factors, warning signs of NAION, and the relative benefits of continued therapy. For clinicians, the evolving evidence underscores the importance of pharmacovigilance: carefully documenting any suspected cases, reporting them to national systems, and staying attuned to future regulatory updates that may refine the understanding of this rare but potentially devastating complication.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
